CRISPR Therapeutics AG (CRSP) Income Statement
CRSP 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCRSP revenue and net income
Where CRSP's revenue goes
2025Each bar shows an amount and its share of revenue. CRSP kept −16,569.8% of revenue as net income.
CRSP profit margins
CRSP growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −90.0% | +100.4% | +37.3% | +30.4% |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CRSP quarterly EPS vs estimates
CRISPR Therapeutics beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 9, 2026 (estimate $-1.07).
CRSP income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.5M | $35.0M | $370.0M | $436,000 | $913.1M | $719,000 | $289.6M | $3.1M | $41.0M | $5.2M |
| Cost of revenue | $233.0M | $110.2M | $130.2M | $110.2M | $101.2M | $269.4M | $179.4M | $113.8M | $69.8M | $42.2M |
| Gross profit | −$229.4M | −$75.2M | $239.8M | −$109.8M | $913.1M | −$268.7M | $289.6M | $3.1M | −$28.8M | −$37.1M |
| Research & development | $265.3M | $320.7M | $387.3M | $461.6M | $438.6M | $221.4M | $179.4M | $113.8M | $69.8M | $42.2M |
| Sales, general & admin | $73.5M | $73.0M | $76.2M | $102.5M | $102.8M | $85.7M | $63.5M | $48.3M | $35.8M | $31.1M |
| Total operating expenses | $338.9M | $391.3M | $462.3M | $563.3M | $539.6M | $85.7M | $242.8M | $162.1M | $105.6M | $73.3M |
| Operating income | −$568.3M | −$466.6M | −$222.5M | −$673.2M | $373.5M | −$354.4M | $46.7M | −$158.9M | −$64.6M | −$68.1M |
| Interest income | — | — | — | — | — | — | $5.5M | $4.3M | $1.8M | $44.6M |
| Interest expense | — | — | — | $46.8M | $24.0M | $6.4M | $25.3M | $0 | $0 | $8.1M |
| Income before taxes | −$578.0M | −$362.7M | −$150.7M | −$650.5M | $379.5M | −$348.1M | $67.3M | −$164.4M | −$66.6M | −$22.7M |
| Income taxes | $3.6M | $3.6M | $2.9M | −$325,000 | $1.9M | $809,000 | $448,000 | $553,000 | $1.7M | $484,000 |
| Net income | −$581.6M | −$366.3M | −$153.6M | −$650.2M | $377.7M | −$348.9M | $66.9M | −$165.0M | −$68.4M | −$23.2M |
| EBITDA | −$558.5M | −$343.4M | −$130.9M | −$649.0M | $391.5M | −$345.3M | $51.5M | −$155.4M | −$61.6M | −$13.7M |
| EPS (diluted) | −$5.41 | −$4.37 | −$1.96 | −$8.37 | $4.42 | −$5.27 | $0.97 | −$3.43 | −$1.72 | $1.05 |
| Gross margin | −6,537.0% | −215.0% | 64.8% | −25,186.7% | 100.0% | −37,369.7% | 100.0% | 100.0% | −70.3% | −717.9% |
| Operating margin | −16,191.4% | −1,333.0% | −60.1% | −154,394.7% | 40.9% | −49,295.5% | 16.1% | −5,087.8% | −157.7% | −1,319.3% |
| Net margin | −16,569.8% | −1,046.4% | −41.5% | −149,122.7% | 41.4% | −48,520.9% | 23.1% | −5,281.1% | −166.7% | −449.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.2M | $1.5M | $864,000 | $889,000 | $892,000 | $865,000 | $35.0M | $602,000 | $517,000 | $504,000 | $200.0M | $0 |
| Cost of revenue | $44.6M | $50.2M | $59.4M | $64.7M | $49.8M | $57.5M | $4.2M | $16.0M | $57.0M | $51.8M | $20.0M | $23.4M |
| Gross profit | −$34.4M | −$48.8M | −$58.5M | −$63.8M | −$48.9M | −$56.6M | $35.0M | −$15.4M | −$56.5M | −$51.3M | $180.0M | −$23.4M |
| Research & development | $65.0M | $68.6M | $77.9M | $58.9M | $65.3M | $72.5M | $82.2M | $77.4M | $75.3M | $71.3M | $95.1M | $90.7M |
| Sales, general & admin | $17.6M | $17.2M | $18.4M | $16.9M | $18.9M | $19.3M | $18.1M | $17.4M | $19.5M | $18.0M | $16.5M | $18.3M |
| Total operating expenses | $80.4M | $81.5M | $96.3M | $68.3M | $84.2M | $91.8M | $99.6M | $94.8M | $94.8M | $89.3M | $110.4M | $109.0M |
| Operating income | −$114.8M | −$130.2M | −$154.8M | −$132.1M | −$133.1M | −$148.4M | −$64.6M | −$110.1M | −$151.3M | −$140.6M | $69.6M | −$132.4M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $17.8M | — |
| Income before taxes | −$90.2M | −$122.1M | −$130.0M | −$105.8M | −$207.3M | −$134.9M | −$36.6M | −$85.1M | −$125.1M | −$115.9M | $89.6M | −$111.7M |
| Income taxes | $960,000 | $839,000 | $614,000 | $619,000 | $1.3M | $1.1M | $700,000 | $876,000 | $1.3M | $724,000 | $233,000 | $412,000 |
| Net income | −$91.2M | −$122.9M | −$130.6M | −$106.4M | −$208.5M | −$136.0M | −$37.3M | −$85.9M | −$126.4M | −$116.6M | $89.3M | −$112.2M |
| EBITDA | −$110.5M | −$117.8M | −$124.3M | −$101.4M | −$202.6M | −$130.2M | −$31.8M | −$80.3M | −$120.3M | −$111.0M | $94.5M | −$106.8M |
| EPS (diluted) | −$0.94 | −$1.28 | −$1.37 | −$1.17 | −$1.29 | −$1.58 | −$0.44 | −$1.01 | −$1.49 | −$1.43 | $1.10 | −$1.41 |
| Gross margin | −337.8% | −3,346.4% | −6,770.8% | −7,177.1% | −5,477.7% | −6,548.4% | 100.0% | −2,550.0% | −10,920.5% | −10,177.6% | 90.0% | — |
| Operating margin | −1,127.6% | −8,933.3% | −17,912.5% | −14,854.8% | −14,918.3% | −17,158.8% | −184.5% | −18,294.0% | −29,257.3% | −27,894.2% | 34.8% | — |
| Net margin | −895.3% | −8,431.5% | −15,117.2% | −11,973.1% | −23,379.9% | −15,722.1% | −106.6% | −14,276.1% | −24,450.3% | −23,133.1% | 44.7% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CRSP's financial statements (latest annual report filed February 12, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CRSP financial results
In fiscal year 2025 (ended December 31, 2025), CRISPR Therapeutics reported revenue of $3.5 million, down 90.0% from the year before. It had a net loss of $581.6 million, a net profit margin of −16,569.8%. Diluted earnings per share came to −$5.41. Over five years revenue grew at an average rate of 37.3% a year.
See the CRSP stock overview for the latest quote and news, or the CRSP chart for price history and technical indicators.
CRSP income statement FAQ
What is CRISPR Therapeutics's annual revenue?
CRISPR Therapeutics reported total revenue of $3.5 million for fiscal year 2025, which ended on December 31, 2025. That was down 90.0% from $35.0 million the previous year.
Is CRISPR Therapeutics profitable?
No. CRISPR Therapeutics reported a net loss of $581.6 million in fiscal 2025, a net profit margin of −16,569.8%; its operating margin was −16,191.4%.
What is CRISPR Therapeutics's gross margin?
CRISPR Therapeutics's gross margin was −6,537.0% in fiscal 2025: for every $100 of revenue, CRISPR Therapeutics kept $-6537 after the direct cost of its products and services.
How much does CRISPR Therapeutics spend on research and development?
CRISPR Therapeutics spent $265.3 million on research and development in fiscal 2025, 7,559.2% of revenue.
How fast is CRISPR Therapeutics growing?
Revenue grew 37.3% a year on average over the last five fiscal years, from $0.7 million to $3.5 million.
What are CRISPR Therapeutics's earnings per share?
CRISPR Therapeutics earned $-5.41 per diluted share in fiscal 2025, compared with $-4.37 a year earlier.
When will CRISPR Therapeutics report its next earnings?
CRISPR Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 after the market closes.
When does CRISPR Therapeutics's fiscal year end?
CRISPR Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 12, 2026.